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ABBREVIATION
EIEE Early infantile epileptic
encephalopathy
Homozygous deletions of chromosome 20p12.3, disrupting the promoter region and first three
coding exons of the phospholipase C b1 gene (PLCB1), have previously been described in two
reports of early infantile epileptic encephalopathy (EIEE). Both children were born to consan-
guineous parents, one presented with infantile spasms, the other with migrating partial seizures
of infancy. We describe an infant presenting with severe intractable epilepsy (without a specific
EIEE electroclinical syndrome diagnosis) and neurodevelopmental delay associated with com-
pound heterozygous mutations in PLCB1. A case note review and molecular genetic investiga-
tions were performed for a child, approximately 10 months of age, admitted to Johns Hopkins
University Hospital for developmental delay and new-onset seizures. The patient presented at
6 months of age with developmental delay, followed by the onset of intractable, focal, and gen-
eralized seizures associated with developmental regression from 10 months of age. Presently,
at 2 years of age, the child has severe motor and cognitive delays. Diagnostic microarray
revealed a heterozygous 476kb deletion of 20p12.3 (encompassing PLCB1), which was also
detected in the mother. The genomic breakpoints for the heterozygous deletion were deter-
mined. In order to investigate the presence of a second PLCB1mutation, direct Sanger sequenc-
ing of the coding region and flanking intronic regions was undertaken, revealing a novel
heterozygous intron 1 splice site variant (c.99+1G>A) in both the index individual and the father.
Advances in molecular genetic testing have greatly improved diagnostic rates in EIEE, and this
report further confirms the important role of microarray investigation in this group of disorders.
PLCB1-EIEE is now reported in a number of different EIEE phenotypes and our report provides
further evidence for phenotypic pleiotropy encountered in early infantile epilepsy syndromes.
An epileptic encephalopathy is defined as a clinical syn-
drome associated with features of encephalopathy that
present or worsen after the onset of epilepsy;1 although it
may present at any age, it is most common in infancy and
early childhood.1,2 The early infantile epileptic encephal-
opathies (EIEEs) are characterized by frequent pharmaco-
resistant seizures, abnormalities on electroencephalography
(EEG), and neurodevelopmental delay or regression.2
Affected individuals are at risk of profound cognitive and
motor impairment in the long term. EIEE can cause con-
siderable hardship for families and the identification of
the underlying aetiology for EIEE continues to present a
significant clinical challenge. The aetiology of EIEE is
heterogeneous, and individuals with EIEE are often found
to have acquired causes (e.g. hypoxic–ischaemic encepha-
lopathy), structural defects (e.g. cortical brain malforma-
tions), or metabolic disorders.3,4 Over the last decade,
rapid developments in molecular genetic techniques have
resulted in a huge increase in the number of reports on
novel genetic causes of EIEE.5,6 Genetic analysis for copy
number variants7,8 and single EIEE candidate genes have,
therefore, become increasingly important investigations in
clinical practice. Recently, homozygous deletions of chro-
mosome 20p12.3, disrupting the promoter region and first
three coding exons of PLCB1, have been described in
individuals with EIEE.9,10 In this report, we describe a
further case of PLCB1-EIEE, thereby expanding the geno-
typic and phenotypic disease spectrum of this genetic
form of infantile epilepsy.
METHOD
Clinical case acquisition
The reported patient was evaluated at Johns Hopkins Uni-
versity Hospital, Baltimore, USA at approximately
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10 months of age for developmental delay and new-onset
seizures. This report has been published with consent from
this patient’s parents.
Molecular genetic investigations
Please see Data S1 (online supporting information) for the
molecular genetic investigation methods.9
RESULTS
Clinical case summary
This female infant was born at 37 weeks’ gestation, after a
typical pregnancy and delivery, with a birthweight of
3230g (25th–50th centile) and head circumference of 35cm
(25th–50th centile). She is of African-American descent,
the second child of healthy non-consanguineous parents,
and has no significant family history. From 6 months of
age, before the onset of seizures, there was some concern
regarding generalized hypotonia and global neurodevelop-
mental delay. By 10 months of age, she developed cata-
strophic onset of seizures characterized by bilateral upper
limb jerking, associated with eye deviation and staring.
The seizures occurred multiple times daily. Some seizures
were prolonged, necessitating admission, on one occasion,
to the intensive care unit.
On examination at presentation, she had typical growth
parameters and her head circumference was on the 75th cen-
tile. There were no dysmorphic features. She was noted to
have right esotropia with right rotatory nystagmus. There
was no iris coloboma or corneal clouding. Axial hypotonia
was evident; however, she had good muscle bulk and typical
deep tendon reflexes. Examination of the cardiovascular,
respiratory, and abdominal systems was unremarkable. Brain
magnetic resonance imaging at 11 months of age revealed
mild global reduction of supratentorial cerebral volume and
a mildly hypoplastic corpus callosum. The image was other-
wise normal, with age-appropriate myelination and neuronal
migration. Electroencephalography (EEG) at the age of
10 months showed a disorganized background, with diffuse
slowing and multifocal spikes throughout the recording
(Fig. S1, online supporting information). Occasional
10-second right and left temporal seizures were also noted.
Clinical and EEG features were not compatible with any
known age-dependent EIEE electroclinical syndrome and
therefore can be classified as non-specific EIEE. Extensive
laboratory investigations (including blood gas, plasma lac-
tate, ammonia, creatine kinase, carnitine profile, very long-
chain fatty acids, transferrin isoelectric focusing, urinary
organic acids, guanidinoacetate, and sulphite, and cerebrosp-
inal fluid lactate, amino acids and glucose) were normal.
Despite trials of multiple antiepileptic drug regimens
there was no significant improvement in seizure control.
A ketogenic diet was implemented with some modest
reduction in seizure frequency. Presently, at 3 years of age,
the patient continues to have approximately four or five
seizures a day, mainly tonic–clonic, and is maintained on
treatment with clobazam and rufinamide. She has axial and
peripheral hypotonia and there is evidence of severe global
neurodevelopmental delay. She is unable to sit or mobilize
independently. She does not reach out to grasp objects but
is able to hold small objects occasionally when these are
placed in her hand. She is able to track objects visually.
She does not vocalize. Owing to an unsafe swallow and
risk of aspiration with liquids, a gastrostomy tube was
recently inserted for fluid intake.
Molecular genetic investigations
A routine diagnostic microarray study identified a heterozy-
gous 476kb deletion on chromosome 20p12.3 from base
pairs (bp) 8 099 252 to 8 575 333 (Human Genome
Build 37; Fig. 1). This deleted region, from rs6140539 to
rs6118262, encompassed part of the 50 region and the first
three coding exons of PLCB1. Microarray studies of paren-
tal DNA confirmed the same heterozygous deletion in the
mother of the proband and absence of the deletion in the
father. The telomeric and centromeric genomic breakpoints
were further characterized and mapped to 8 094 442 to
8 094 510 bp and 8 580 654 to 8 580 722 bp respectively
(Fig. 2). Further analysis revealed that the telomeric and
centromeric breakpoints lie within two L1 family long
interspersed nuclear elements (LINEs), LIPA3 and LIPA2,
occurring at chromosome 20, 8 089 514 to 8 095 564 bp,
and chromosome 20, 8 575 749 to 8 581 774 bp. In order
to determine whether the proband harboured a second
PLCB1 mutation on the paternally derived allele, direct
Sanger sequencing was performed of the whole coding
sequence of PLCB1 (including flanking exon–intron bound-
aries) for the child and both parents. This revealed a splice
site variant in intron 1 (c.99+1G>A) in both the index indi-
vidual and in the father (Fig. 2). This splice site mutation,
affecting the first base after exon 1, was predicted to cause
deleterious splicing (Berkeley Drosophila Genome project:
www.fruitfly.org/seq_tools/splice.html), thereby either lead-
ing to nonsense-mediated decay or a truncated protein
product.
DISCUSSION
We report a novel case of PLCB1-EIEE (OMIM EIEE12;
#613722) with compound heterozygous gene mutations.
Our report highlights a new phenotype for PLCB1-EIEE
as well as a previously unreported point mutation.
PLCB1 encodes the phosphoinositide-specific enzyme,
phospholipase C b1. It is activated by G-proteins and
catalyzes the generation of second messengers, inositol
1,4,5-triphosphate and diacylglycerol from phosphatidyl-
inositol 4,5-biphosphate, an essential step in the intracellu-
lar transduction of a large number of extracellular
signals.11 PLCB1 plays an important role in modulating
diverse developmental and functional aspects of the central
What this paper adds
• It contributes to awareness of the different electroclinical phenotypes of
PLCB1-related EIEE, and provides further evidence of phenotypic pleiotropy
and genetic heterogeneity in EIEE.
• It emphasises the importance of microarray studies as an early investigation
in EIEE.
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nervous system.12 In the murine model, biallelic knock-out
of plcb1 results in an epileptic phenotype.13 At a cellular
level, it is postulated that PLCB1 deficiency selectively
impairs muscarinic acetylcholine receptor signalling,
thereby disrupting normal inhibitory neuronal circuitry,
increasing neuronal excitability, and lowering the seizure
threshold.9,13
Our patient represents the third case of PLCB1-EIEE
reported in the literature. Notably, our case differs from
the previously described cases in both genotype and phe-
notype. The first reported case from 2010 had catastrophic
onset of focal and tonic seizures in early infancy with evo-
lution into West syndrome at 8 months of age.9 The sec-
ond case had a different electroclinical diagnosis of
malignant migrating partial seizures in infancy.10 Our
patient represents a case of non-specific EIEE. Despite
these differences, there are a number of common features
including (1) seizure onset in infancy; (2) pharmacoresis-
tant seizures; (3) abnormalities on EEG; (4) neurological/
developmental regression associated with seizures; and
(5) long-term cognitive and motor neurodevelopmental
impairment.
Our findings also highlight the extensive phenotypic
pleiotropy seen in EIEE, clearly illustrated by other cases
of genetic EIEE such as those due to mutations in
STXBP1,14–17 ARX,6,18 and SCN1A.19,20 Phenotypic pleiot-
ropy and genetic heterogeneity are increasingly recognized
in EIEE. Whilst in general terms, such advances in
improved genetic diagnosis are highly beneficial, on
another level, it certainly renders genetic investigation of
EIEE a diagnostic challenge for the clinician.21 It is likely
that, in the future, (1) single gene testing will be limited to
situations in which the clinical history and phenotype are
highly suggestive of a specific gene; and (2) targeted mas-
sively parallel resequencing/multiple gene panels for candi-
date EIEE genes (including PLCB1) will play an
increasingly important role.22
Our report further emphasizes the importance of diag-
nostic microarray analysis in EIEE.8,21 Detection of the
heterozygous deletion on chromosome 20p12.3 prompted
further genetic investigation of PLCB1 and the identifica-
tion of the second point mutation, thereby leading to the
diagnosis of PLCB1-EIEE. Rare copy number variants are
increasingly recognized as an important cause of EIEE,
and chromosomal microarray analysis should be carried
out as an early investigation in the diagnostic work-up of
such cases.7,21 Whilst both of the cases of PLCB1-EIEE
previously reported were associated with a homozygous
PLCB1 deletion,9,10 our patient was found to harbour a
heterozygous deletion in tandem with an intron 1 splice
site variant.
Interestingly, the deletion detected in this patient has
almost identical breakpoints to those described in the
individual with West Syndrome PLCB1-EIEE.9 It is likely
that the LINEs (which represent highly homologous repet-
itive sequences) at the breakpoint sites predispose to
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Figure 1: Molecular genetics results data. Panel (a) and (b): Microarray data. Single nucleotide polymorphism array data for chromosome 20 (panel [a])
and the region at 20p12.3 (panel [b]) from the index individual are shown. Relative AB allele frequencies and LogR ratio intensity are indicated. The
476kb deleted region at 20p12.3 in the index individual is highlighted by a red horizontal bar (panels [a] and [b]). The deleted region includes the first
three coding exons of PLCB1 (panel [b]).
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chromosomal rearrangements, thereby playing an impor-
tant mechanistic role in the way in which recurrent dele-
tions occur. The second point mutation described in our
individual is a novel splice site variant affecting the first
base after exon 1 of PLCB1. To date, no point mutations
have yet been described in PLCB1-EIEE and our report,
therefore, provides further insight into other disease
causing mutations within the spectrum of PLCB1-EIEE.
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8,095,564 bp 8,113,272 bp
100% sequence homology between upstream and intron 3-4 sequence
Upstream sequence
Intronic sequence
Father (c.99+1G/A) Patient (c.99+1A/A)
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8,094,510 bp
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Figure 2: Definition of the genomic breakpoints of the deletion and sequence chromatograms. (a) Schematic diagram of PLCB1 gene comprising upstream
region and exon 1 to 4 with localization of repetitive long interspersed elements. (b) Sequence chromatogram of long range polymerase chain reaction
product encompassing breakpoints which are located between 8 094 442 and 8 094 510 bp in upstream sequence and 8 580 654 and 8 580 722 bp in
intron 3 sequence. A 68 bp sequence which showed 100% sequence homology for both upstream and intron 3 sequence is highlighted by a yellow box.
(c) Comparison of upstream and intron 3 sequence flanking the breakpoint. Differences highlighted by turquoise (upstream sequence) and purple (intronic
sequence). (d) Sequence chromatogram from father of index individual. (e) Sequence chromatogram from the index individual. As illustrated, this splice
site change appears heterozygous in the father but appears homozygous in the affected child due to absence of the deleted allele.
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Identification of both of the disease-causing mutations in
our patient allowed us to confirm a genetic cause for this
patient’s EIEE. Establishing a genetic aetiology for an
individual’s epilepsy affords a number of benefits. It
provides families with accurate information about risk of
recurrence and thereby facilitates prepregnancy counsel-
ling, prenatal diagnosis, and preimplantation diagnosis.
Confirmation of a genetic diagnosis can also help limit
more invasive diagnostic investigations (such as lumbar
puncture and tissue biopsy). For certain genetic disorders,
diagnosis can guide treatment23,24 and discussions regard-
ing prognosis.24,25 From a broader perspective, identifica-
tion of causative genes contributes greatly to the
understanding of disease mechanisms in EIEE and it is
also likely that it will pave the way for the development of
novel targeted drug therapies.
CONCLUSION
In conclusion, we report a novel case of PLCB1-EIEE in an
child presenting with developmental delay and epilepsy.
Autosomal recessive PLCB1-EIEE is an emerging cause of
infantile epileptic encephalopathy, causing a number of
different electroclinical phenotypes. It is likely that such
genetic characterization of EIEE cases will lead to a better
understanding of genotypes and phenotypes, as well as
more elucidation of disease mechanisms and therapeutic
strategies.
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